Hermetica Superfood Encyclopedia
The Short Answer
Dunaliella tertiolecta produces two primary classes of bioactive compounds—the xanthophyll carotenoid zeaxanthin, which accumulates under high-salinity and high-light conditions, and a structurally complex galactolipid (glycerol 1-(9Z,12Z,15Z-octadecatrienoate)-2-(4Z,7Z,10Z,13Z-hexadecatetraenoate)-3-O-β-D-galactopyranoside, C₄₃H₆₈O₁₀) with potent antiproliferative activity. In vitro fractions of this alga reduced viability of HepG2, HCC-827, Calu-3, and A2058 melanoma cell lines to 9–44% at 100 μg/mL after 72 hours, while sparing normal human MRC-5 fibroblasts, representing the most quantified biological effect reported to date.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary KeywordDunaliella tertiolecta benefits
Dunaliella tertiolecta — botanical close-up
Health Benefits
**Antiproliferative Activity Against Cancer Cell Lines**
Purified lipid fractions (D and E) containing the galactolipid C₄₃H₆₈O₁₀ reduced viability of hepatocellular (HepG2), lung (HCC-827, Calu-3), and melanoma (A2058) cell lines to 9–45% at 100 μg/mL in MTT assays after 72 hours, suggesting selective cytotoxic potential not yet validated in vivo.
**Antioxidant Capacity via Zeaxanthin Accumulation**
Zeaxanthin, a xanthophyll carotenoid that accumulates at 1.5–3.0 M NaCl salinity in optimized cultures, scavenges reactive oxygen species and may quench singlet oxygen; engineered strain mp3 produces 10–15% higher zeaxanthin content than the parent strain zea1, enhancing antioxidant yield per biomass unit.
**Potential Eye Health Support via Zeaxanthin**
Zeaxanthin is a macular pigment that filters high-energy blue light and reduces oxidative stress in retinal photoreceptors; although clinical data specific to D. tertiolecta-derived zeaxanthin are absent, the compound class has established mechanistic relevance to age-related macular degeneration risk reduction.
**Antimicrobial Properties**: Optimized culture extracts (1
5–2.0 g/L nitrogen, 3600–4800 lux, 15–25% NaCl, 7–28 days) produced inhibition zones up to 18 mm against Bacillus subtilis and 14 mm against Escherichia coli O157:H7 in disk diffusion assays, indicating broad-spectrum antibacterial activity that warrants further mechanistic characterization.
**Glutathione Elevation Under Stress Conditions**
Total glutathione (TGSH), quantified via DTNB assay, is elevated in cultures maintained under low-nitrogen and high-light stress; glutathione is a critical intracellular antioxidant and detoxification cofactor, suggesting D. tertiolecta biomass may carry endogenous antioxidant enzymes alongside pigment compounds.
**Selective Normal-Cell Sparing (In Vitro Safety Signal)**
Total extracts and isolated fractions at 10–100 μg/mL did not reduce viability of normal human MRC-5 lung fibroblasts in three independent biological replicates, providing a preliminary therapeutic index signal that distinguishes this alga's lipid fractions from indiscriminately cytotoxic agents.
Origin & History
Natural habitat
Dunaliella tertiolecta is a unicellular, halotolerant green microalga (Division Chlorophyta) native to marine and hypersaline aquatic environments worldwide, including coastal waters, salt lakes, and brine pools where salinity ranges from near-freshwater to saturated NaCl solutions. It thrives under high-salinity conditions (1.5–3.0 M NaCl), elevated light intensities, and nutrient-variable media, making it adaptable to open-pond and photobioreactor cultivation systems used in biotechnology research. Unlike terrestrial botanicals, it has no traditional agricultural cultivation history and is grown exclusively under controlled laboratory or industrial fermentation conditions for research and potential commercial pigment production.
“Dunaliella tertiolecta has no documented history of use in any traditional medicine system, indigenous healing practice, or cultural culinary tradition. The genus Dunaliella gained scientific attention in the late 20th century primarily through its close relative Dunaliella salina, which is commercially cultivated for beta-carotene production and has been used as a nutritional supplement since the 1980s; D. tertiolecta was identified as a distinct halotolerant species of biotechnological interest largely through molecular phylogenetics and pigment profiling studies conducted in the 1990s and 2000s. Research interest in D. tertiolecta has grown specifically in the context of marine natural product drug discovery and renewable biofuel feedstock development, rather than from any ethnobotanical or traditional use foundation. The species remains a laboratory and pilot-scale research organism, with no established preparation method, folk formulation, or historical precedent for human consumption.”Traditional Medicine
Scientific Research
The available evidence base for Dunaliella tertiolecta is limited exclusively to in vitro cell culture experiments and microbiological disk diffusion assays, with no animal pharmacology studies or human clinical trials published to date. The most substantive published work involves MTT-based cytotoxicity screening of SPE-fractionated extracts (fractions A–E) against four cancer cell lines at concentrations of 10–100 μg/mL (n=3 biological replicates), and HPLC-UV-HRMS/NMR structural elucidation of the active galactolipid from clone CCMP 1320; this represents mechanistically interesting but early-stage preliminary data. Zeaxanthin yield optimization has been quantified in engineered strain mp3 under defined salinity gradients (1.5–3.0 M NaCl) with statistical significance reported at p < 0.05, and total carotenoid content has been measured spectrophotometrically at approximately 4.0 μg/mL in optimized cultures, constituting reproducible but non-clinical analytical chemistry. Collectively, the evidence corresponds to a preclinical discovery phase; translation to demonstrated human health benefits requires dose-finding pharmacokinetics, animal toxicology, and randomized controlled trials, none of which have been conducted.
Preparation & Dosage
Traditional preparation
**Laboratory Research Extract (In Vitro Use Only)**
Total solvent extracts of stationary-phase biomass from clone CCMP 1320, tested at 10–100 μg/mL in cell culture; no equivalent human dose established.
**SPE Fractions (A–E, Research Grade)**
Solid-phase extraction separates biomass into amino acid/saccharide (A), nucleoside (B), glycophospholipid (C), free fatty acid/sterol (D), and triglyceride-rich (E) fractions; fractions D and E carry the primary antiproliferative galactolipid.
**Zeaxanthin-Enriched Biomass**
Achieved by culturing engineered strain mp3 at 1.5–3.0 M NaCl, low nitrogen, and high light intensity; yields approximately 4.0 μg/mL total carotenoids spectrophotometrically; no standardized supplement form exists.
**Antimicrobial Optimized Biomass**
0 g/L nitrogen, 3600–4800 lux illumination, 15–25% NaCl, 7–28 days culture duration; preparation method is laboratory-scale only
Produced under 1.5–2..
**No Established Human Supplement Form or Dose**
No commercial capsule, powder, or liquid formulation has been standardized or approved; all dosing references are in vitro concentrations that cannot be directly extrapolated to oral human doses without pharmacokinetic data.
Nutritional Profile
Dunaliella tertiolecta biomass contains a complex mixture of photosynthetic pigments, lipids, and primary metabolites whose concentrations vary substantially with culture conditions. Carotenoids total approximately 4.0 μg/mL in optimized cultures, with zeaxanthin as the primary xanthophyll; chlorophyll a is estimated by the formula ~12.25 × Abs₆₆₄ − 2.55 × Abs₆₄₇ μg/mL and chlorophyll b by ~20.31 × Abs₆₄₇ − 4.91 × Abs₆₆₄ μg/mL under standard spectrophotometric conditions. Lipid fractions include glycolipids (notably the C₄₃H₆₈O₁₀ galactolipid), glycophospholipids, free fatty acids including polyunsaturated species (18:3 and 16:4 acyl chains confirmed by NMR), sterols, and triglycerides; free amino acids, saccharides, and nucleosides are also present in polar fractions. Total glutathione is quantifiable via DTNB assay and is elevated under low-nitrogen, high-light stress conditions, but absolute concentrations relative to dry weight have not been standardized for nutritional labeling purposes; no comprehensive proximate analysis (protein, carbohydrate, total lipid percentages) per gram dry weight is available in published literature for this specific species.
How It Works
Mechanism of Action
The primary antiproliferative mechanism is attributed to the galactolipid glycerol 1-(9Z,12Z,15Z-octadecatrienoate)-2-(4Z,7Z,10Z,13Z-hexadecatetraenoate)-3-O-β-D-galactopyranoside (C₄₃H₆₈O₁₀), identified via HPLC-UV-HRMS and confirmed by NMR from SPE fractions D and E of clone CCMP 1320; although the precise intracellular targets remain uncharacterized, structurally analogous galactolipids from other microalgae are known to inhibit DNA polymerases, disrupt membrane integrity in rapidly dividing cells, and modulate phospholipase A₂ activity. Zeaxanthin exerts antioxidant activity primarily by physical quenching of singlet oxygen and triplet chlorophyll within lipid bilayers, and by donating electrons to terminate radical chain reactions; its accumulation under osmotic and light stress is mediated through upregulation of carotenoid biosynthesis genes and xanthophyll cycle enzymes including violaxanthin de-epoxidase. Antimicrobial compounds produced under optimized nitrogen and salinity conditions likely compromise bacterial membrane function, though specific targets such as lipopolysaccharide disruption or efflux pump inhibition have not been confirmed for D. tertiolecta specifically. No human receptor-level, transcriptomic, or proteomic data are currently available for any D. tertiolecta fraction, limiting mechanistic conclusions to the cellular and biochemical level.
Clinical Evidence
No clinical trials in human subjects have been conducted with Dunaliella tertiolecta extracts, fractions, or derived compounds in any health condition. The totality of quantified efficacy data derives from in vitro MTT viability assays showing 9–45% residual cancer cell viability at 100 μg/mL (fractions D/E, 72-hour exposure) and antimicrobial inhibition zones of 14–18 mm in disk diffusion assays—outcomes that, while statistically measurable, do not translate directly to clinical effect sizes. No pharmacokinetic data, bioavailability estimates, maximum tolerated doses, or patient-reported outcomes have been established for any human population. Confidence in clinical efficacy is therefore extremely low; the ingredient should be regarded as a research-stage compound with unproven therapeutic application in humans.
Safety & Interactions
Dunaliella tertiolecta extracts showed no cytotoxicity toward normal human MRC-5 lung fibroblasts at concentrations of 10–100 μg/mL in vitro (three biological replicates), which is the only safety-relevant data currently published; this finding cannot be extrapolated to oral human safety without in vivo toxicology studies. No drug interaction data, contraindication profiles, pregnancy or lactation guidance, or maximum tolerated dose information exist for any D. tertiolecta preparation in humans or animals. Given the complete absence of in vivo pharmacology or human safety studies, this ingredient should not be considered safe for human supplementation outside of formally approved clinical research protocols with appropriate institutional ethics oversight. Individuals with algae allergies or iodine sensitivity should exercise theoretical caution, though no allergenicity data specific to D. tertiolecta have been published.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Dunaliella tertiolecta Butcher 1959D. tertiolectaCCMP 1320 (culture collection clone)halotolerant green microalga
Frequently Asked Questions
What is Dunaliella tertiolecta used for in supplements?
Dunaliella tertiolecta is investigated primarily as a source of zeaxanthin, a xanthophyll carotenoid associated with eye health and antioxidant protection, and of a structurally unique galactolipid (C₄₃H₆₈O₁₀) with demonstrated antiproliferative activity in cancer cell lines. However, no commercial supplement has been standardized from this species, and no human clinical trials have established an effective or safe dose for any health indication.
Does Dunaliella tertiolecta have anti-cancer properties?
In laboratory cell culture studies, lipid-rich fractions (D and E) from D. tertiolecta extract reduced viability of HepG2 liver, HCC-827 and Calu-3 lung, and A2058 melanoma cell lines to 9–45% at 100 μg/mL after 72 hours, while normal MRC-5 fibroblasts were unaffected. These results are preliminary in vitro findings only; no animal studies or human clinical trials have been conducted, so anti-cancer claims in humans are not scientifically supported.
How does Dunaliella tertiolecta differ from Dunaliella salina?
Dunaliella salina is the commercially dominant species in the genus, primarily cultivated for mass beta-carotene production and used as a nutritional supplement globally since the 1980s. Dunaliella tertiolecta is a distinct halotolerant species that accumulates zeaxanthin rather than beta-carotene as its primary xanthophyll and has been identified as a source of unique antiproliferative galactolipids, but it has no established commercial supplement form or history of human use comparable to D. salina.
What is the zeaxanthin content of Dunaliella tertiolecta?
Zeaxanthin content in D. tertiolecta is maximized under salinity conditions of 1.5–3.0 M NaCl combined with low nitrogen and high light intensity; the engineered strain mp3 produces 10–15% more zeaxanthin than its parent strain zea1. Total carotenoid content in optimized cultures measures approximately 4.0 μg/mL by spectrophotometry at 480 nm, though zeaxanthin-specific quantification as a percentage of dry biomass has not been published in standardized form.
Is Dunaliella tertiolecta safe to consume?
The only available safety data shows that D. tertiolecta extracts at 10–100 μg/mL did not harm normal human MRC-5 fibroblasts in cell culture, but no animal toxicology studies, pharmacokinetic data, or human clinical safety trials have been conducted. Without in vivo and clinical safety data, the ingredient cannot be considered established as safe for human consumption, and it is not currently approved or regulated as a dietary supplement ingredient in any major jurisdiction.
What is the bioavailability of lipid fractions from Dunaliella tertiolecta?
Dunaliella tertiolecta's bioactive lipids, particularly the galactolipid fraction, are fat-soluble compounds that require dietary fat for optimal absorption in the gastrointestinal tract. The microalgae's natural lipid matrix may enhance bioavailability compared to isolated compounds, though human absorption studies remain limited. Consuming Dunaliella tertiolecta extracts with meals containing healthy fats can improve the uptake of its zeaxanthin and other lipophilic bioactives.
Who would benefit most from Dunaliella tertiolecta supplementation?
Individuals seeking eye health support due to zeaxanthin's role in macular health and those interested in antioxidant protection may benefit from Dunaliella tertiolecta. People with limited dietary intake of carotenoid-rich foods or those at risk for oxidative stress-related conditions represent potential target populations. However, most evidence comes from in vitro studies, so benefits in specific populations require further clinical validation.
How does the extraction method affect the potency of Dunaliella tertiolecta supplements?
The extraction method directly influences which bioactive fractions are concentrated, particularly the cytotoxic lipid fractions (D and E) and zeaxanthin content studied in research. Lipid-based extraction methods may better preserve the galactolipid compounds responsible for observed antiproliferative activity in cell studies. Different extraction protocols can yield supplements with significantly varying potencies, making product selection important for consistent bioactive delivery.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w dunaliella-tertiolecta-microalgae curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
